Rituximab/IVIG in pemphigus – a 10-year study with a long follow-up

References

• Horvath B, Huizinga J, Pas HH, et al. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166:405–412.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043–1046.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. Curr CDDT. 2009;6:270–280.
   Google Scholar
• Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130:2041–2048.
   PubMed Web of Science ®Google Scholar
• Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60:595–603.
   PubMed Web of Science ®Google Scholar
• Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity. 2006;39:609–616.
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–445.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793–2806.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603–3613.
   PubMed Web of Science ®Google Scholar
• Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142–144.
   PubMed Web of Science ®Google Scholar
• Cianchini G, Lupi F, Masini C, et al. Therapy with rituximab for autoimmune pemphigus: results from a single center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67:617–622.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65:552–558.
   PubMed Web of Science ®Google Scholar
• Reguiai Z, Tabary T, Maizieres M, et al. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol. 2012; 67:623–629.
   PubMed Web of Science ®Google Scholar
• Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148:1031–1036.
   PubMedGoogle Scholar
• Balighi K, Daneshpazhooh M, Khezri S, et al. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–867.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–1779.
   PubMed Web of Science ®Google Scholar
• Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol. 2008;158:382–388.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YH, Kim MR, et al. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165:646–651.
   PubMed Web of Science ®Google Scholar
• Leshem YA, Hodak E, David M, et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404–411.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Tsuruta D, Vinay K, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27:e17–e23.
   PubMed Web of Science ®Google Scholar
• Robinason AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: protocol and single-centre long-term review of nine patients. Australas J Dermatol. 2018;59(1):e47–e52.
   PubMed Web of Science ®Google Scholar
• Joly P, Mouquet H, Roujeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–552.
   PubMed Web of Science ®Google Scholar
• Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011;65:1064–1065.
   PubMed Web of Science ®Google Scholar
• Saskia I-H-O, Laurence V-A, Anne C, et al. First-line Treatment of Pemphigus Vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015;151:200–203.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T. Intravenous immunoglobulins in the prevention of infection in children with hematologic-oncologic diseases. Klin Padiatr. 2001;213:A103–A105.
   PubMed Web of Science ®Google Scholar
• Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:117–130.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323:705–712.
   PubMed Web of Science ®Google Scholar
• Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005;1051:743–778.
   PubMed Web of Science ®Google Scholar
• Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7:529–541.
   PubMed Web of Science ®Google Scholar
• Cho HH, Jin SP, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2014; 28:186–191.
   PubMed Web of Science ®Google Scholar
• Cho Y-T, Lee F-Y, Chu C-Y, et al. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014; 94:472–473.
   PubMed Web of Science ®Google Scholar
• Heelan K, Al-Mohammedi F, Smith MJ, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150:703–708.
   PubMed Web of Science ®Google Scholar
• Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5:175ra30.
   PubMed Web of Science ®Google Scholar
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–2040.
   PubMed Web of Science ®Google Scholar
• Vinay K, Cazzaniga S, Amber KT, et al. Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018;78:806–808.
   PubMed Web of Science ®Google Scholar
• Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143:1033–1038.
   PubMedGoogle Scholar